Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease

NCT00599196 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00599196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00599196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2002
Completion date
December 31, 2008
Enrollment
381 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

early stage parkinson's disease